Skip to main content
Erschienen in: Journal of General Internal Medicine 8/2008

01.08.2008 | Original Article

Does a History of Non-Vertebral Fracture Identify Women Without Osteoporosis for Treatment?

verfasst von: Kathryn M. Ryder, MD, MS, Steven R. Cummings, MD, Lisa Palermo, MS, Suzanne Satterfield, MD, DrPH, Douglas C. Bauer, MD, Adrianne C. Feldstein, MD, MS, John T. Schousboe, MD, MS, Ann V. Schwartz, PhD, Kristine Ensrud, MD, MPH, for the Fracture Intervention Trial Research Group

Erschienen in: Journal of General Internal Medicine | Ausgabe 8/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

Postmenopausal women with a prior fracture have an increased risk for future fracture. Whether a history of non-vertebral fracture defines a group of women with low bone mass but without osteoporosis for whom alendronate would prevent new non-vertebral fracture is not known.

Subjects and Methods

Secondary analysis of data from the Fracture Intervention Trial (FIT). Of 2,785 postmenopausal women with a T-score at the femoral neck between −1 and −2.5 and without prevalent radiographic vertebral deformity, 880 (31.6%) reported experiencing a fracture after 45 years of age. Women were randomized to placebo or alendronate (5 mg/day years for the first 2 years and 10 mg/day thereafter) and were followed for an average of 4.2 ± 0.5 years. Incident non-vertebral fractures were confirmed by x-rays and radiology reports.

Results

In the placebo arm, a self-report of prior fracture identified women with a 1.5-fold (hazard ratio [RH] 1.46, 95% C.I. 1.04–2.04) increased risk for incident non-vertebral fracture. However, there was no evidence that the effect of alendronate differed across subgroups of women with (RH 1.26 for alendronate vs placebo, 95% C.I. 0.89–1.79) and without prior fracture (RH 1.02 for alendronate vs placebo, 95% C.I. 0.76–1.38; P = 0.37 for interaction).

Conclusion

Assessing a clinical risk factor, prior non-vertebral fracture, did not identify women with low bone mass for whom alendronate reduced future non-vertebral fracture risk.
Literatur
1.
Zurück zum Zitat Looker AC, Orwoll ES, Johnston CC Jr, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12:1761–8.PubMedCrossRef Looker AC, Orwoll ES, Johnston CC Jr, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12:1761–8.PubMedCrossRef
2.
Zurück zum Zitat Wainwright SA, Marshall LM, Ensrud KE, et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab. 2005;90:2787–93.PubMedCrossRef Wainwright SA, Marshall LM, Ensrud KE, et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab. 2005;90:2787–93.PubMedCrossRef
3.
Zurück zum Zitat Sanders KM, Pasco JA, Ugoni AM, et al. The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community. J Bone Miner Res. 1998;13:1337–42.PubMedCrossRef Sanders KM, Pasco JA, Ugoni AM, et al. The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community. J Bone Miner Res. 1998;13:1337–42.PubMedCrossRef
4.
Zurück zum Zitat Schuit SCE, van der Klift M, Weel AEAM, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004;34:195–202.PubMedCrossRef Schuit SCE, van der Klift M, Weel AEAM, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004;34:195–202.PubMedCrossRef
5.
Zurück zum Zitat Stone KL, Seeley DG, Lui L-Y, et al. BMD at multiple sites and risk of fractures of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res. 2003;18:1947–54.PubMedCrossRef Stone KL, Seeley DG, Lui L-Y, et al. BMD at multiple sites and risk of fractures of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res. 2003;18:1947–54.PubMedCrossRef
6.
Zurück zum Zitat Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164:1108–12.PubMedCrossRef Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164:1108–12.PubMedCrossRef
7.
Zurück zum Zitat Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M. Patients with prior fracture have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15:721–39.PubMedCrossRef Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M. Patients with prior fracture have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15:721–39.PubMedCrossRef
8.
Zurück zum Zitat Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332:767–73.PubMedCrossRef Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1995;332:767–73.PubMedCrossRef
9.
Zurück zum Zitat Nguyen T, Sambrook P, Kelly P, et al. Prediction of osteoporotic fractures by postural instability and bone density. BMJ. 1993;307:1111–5.PubMed Nguyen T, Sambrook P, Kelly P, et al. Prediction of osteoporotic fractures by postural instability and bone density. BMJ. 1993;307:1111–5.PubMed
10.
Zurück zum Zitat Dargent-Molina P, Faviier F, Grandjean H, et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet. 1996;348:145–9.PubMedCrossRef Dargent-Molina P, Faviier F, Grandjean H, et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet. 1996;348:145–9.PubMedCrossRef
11.
Zurück zum Zitat National Osteoporosis Foundation. Physician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 1998. National Osteoporosis Foundation. Physician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 1998.
12.
Zurück zum Zitat American Association of Clinical Endocrinology. Medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates from 2003. Endocrine Pract. 2003;9:544–64. American Association of Clinical Endocrinology. Medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates from 2003. Endocrine Pract. 2003;9:544–64.
13.
Zurück zum Zitat Siris ES, Genant HK, Laster AJ, et al. Enhanced prediction of fracture risk combining vertebral fracture status and BMD. Osteoporos Int. 2007;18:761–70.PubMedCrossRef Siris ES, Genant HK, Laster AJ, et al. Enhanced prediction of fracture risk combining vertebral fracture status and BMD. Osteoporos Int. 2007;18:761–70.PubMedCrossRef
14.
Zurück zum Zitat Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk. Arch Intern Med. 1997;157:2614–7. Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk. Arch Intern Med. 1997;157:2614–7.
15.
Zurück zum Zitat Quandt SA, Thompson DE, Schneider DL, et al. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of −1.6 to −2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc. 2005;80:343–9.PubMedCrossRef Quandt SA, Thompson DE, Schneider DL, et al. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of −1.6 to −2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc. 2005;80:343–9.PubMedCrossRef
16.
Zurück zum Zitat Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone mineral density but without vertebral fractures. JAMA. 1998;280:2077–82.PubMedCrossRef Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone mineral density but without vertebral fractures. JAMA. 1998;280:2077–82.PubMedCrossRef
17.
Zurück zum Zitat Schousboe JT, Nyman JA, Kane RL, Ensrud KE. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med. 2005;142:734–41.PubMed Schousboe JT, Nyman JA, Kane RL, Ensrud KE. Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med. 2005;142:734–41.PubMed
18.
Zurück zum Zitat Schousboe JT, Ensrud KE, Nyman JA, et al. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporosis Int. 2005;16:1883–93.CrossRef Schousboe JT, Ensrud KE, Nyman JA, et al. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporosis Int. 2005;16:1883–93.CrossRef
19.
Zurück zum Zitat McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333–40.PubMedCrossRef McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333–40.PubMedCrossRef
20.
Zurück zum Zitat Sornay-Rendu E, Munoz F, Garnero P, et al. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res. 2005;20:1813–9.PubMedCrossRef Sornay-Rendu E, Munoz F, Garnero P, et al. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res. 2005;20:1813–9.PubMedCrossRef
21.
Zurück zum Zitat Johnell O, Kanis JA, Oden A, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int. 2004;15:175–9.PubMedCrossRef Johnell O, Kanis JA, Oden A, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int. 2004;15:175–9.PubMedCrossRef
22.
Zurück zum Zitat Miller PD, Barlas S, Brenneman SK, et al. An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med. 2004;164:1113–20.PubMedCrossRef Miller PD, Barlas S, Brenneman SK, et al. An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med. 2004;164:1113–20.PubMedCrossRef
23.
Zurück zum Zitat Black DM, Reiss TF, Nevitt MC, et al. Design of the fracture intervention trial. Osteoporos Int. 1993;3(suppl):3S29–S39.PubMedCrossRef Black DM, Reiss TF, Nevitt MC, et al. Design of the fracture intervention trial. Osteoporos Int. 1993;3(suppl):3S29–S39.PubMedCrossRef
24.
Zurück zum Zitat Genant HK, Jergas M, van Kuijk C, eds. Vertebral Fracture in Osteoporosis. San Francisco, Calif: Radiology Research and Educational Foundation; 1995:131–147. Genant HK, Jergas M, van Kuijk C, eds. Vertebral Fracture in Osteoporosis. San Francisco, Calif: Radiology Research and Educational Foundation; 1995:131–147.
25.
Zurück zum Zitat Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA. 1999;282:1344–52.PubMedCrossRef Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA. 1999;282:1344–52.PubMedCrossRef
26.
Zurück zum Zitat Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11:83–91.PubMedCrossRef Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11:83–91.PubMedCrossRef
27.
Zurück zum Zitat Chestnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241–9.CrossRef Chestnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241–9.CrossRef
28.
Zurück zum Zitat Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–41.PubMedCrossRef Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–41.PubMedCrossRef
29.
Zurück zum Zitat Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. the Women’s Health Initiative Randomized Trial. JAMA. 2003;290:1729–38.PubMedCrossRef Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. the Women’s Health Initiative Randomized Trial. JAMA. 2003;290:1729–38.PubMedCrossRef
30.
Zurück zum Zitat Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125–37.PubMedCrossRef Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125–37.PubMedCrossRef
31.
Zurück zum Zitat Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–1809.PubMedCrossRef Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799–1809.PubMedCrossRef
32.
Zurück zum Zitat Gallacher SJ, Gallagher AP, McQuillian C, et al. The prevalence of vertebral fracture amongst patients presenting with non-vertebral fractures. Osteoporos Int. 2007;18:185–92.PubMedCrossRef Gallacher SJ, Gallagher AP, McQuillian C, et al. The prevalence of vertebral fracture amongst patients presenting with non-vertebral fractures. Osteoporos Int. 2007;18:185–92.PubMedCrossRef
33.
Zurück zum Zitat Bauer DC, Garnero P, Hochberg MC, et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the Fracture Intervention Trial. J Bone Miner Res. 2006;21:292–9.PubMedCrossRef Bauer DC, Garnero P, Hochberg MC, et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the Fracture Intervention Trial. J Bone Miner Res. 2006;21:292–9.PubMedCrossRef
34.
Zurück zum Zitat Schousboe JT, Bauer DC, Nyman KA, et al. Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporos Int. 2007;18:201–10.PubMedCrossRef Schousboe JT, Bauer DC, Nyman KA, et al. Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporos Int. 2007;18:201–10.PubMedCrossRef
35.
Zurück zum Zitat Nevitt MC, Cummings SR, Browner WS, et al. The accuracy of self-report of fractures in elderly women: evidence from a prospective study. Am J Epidemiol. 1992;135:490–9.PubMed Nevitt MC, Cummings SR, Browner WS, et al. The accuracy of self-report of fractures in elderly women: evidence from a prospective study. Am J Epidemiol. 1992;135:490–9.PubMed
36.
Zurück zum Zitat Hundrup YA, Hoidrop S, Obel EB, Rasmussen NK. The validity of self-reported fractures among Danish female nurses: comparison with fractures registered in the Danish National Hospital Register. Scand J Pub Health. 2004;32:136–43.CrossRef Hundrup YA, Hoidrop S, Obel EB, Rasmussen NK. The validity of self-reported fractures among Danish female nurses: comparison with fractures registered in the Danish National Hospital Register. Scand J Pub Health. 2004;32:136–43.CrossRef
37.
Zurück zum Zitat Ivers RQ, Cummings RG, Mitchell P, Peduto AJ. The accuracy of self-reported fractures in older people. J Clin Epidemiol. 2002;55:452–7.PubMedCrossRef Ivers RQ, Cummings RG, Mitchell P, Peduto AJ. The accuracy of self-reported fractures in older people. J Clin Epidemiol. 2002;55:452–7.PubMedCrossRef
Metadaten
Titel
Does a History of Non-Vertebral Fracture Identify Women Without Osteoporosis for Treatment?
verfasst von
Kathryn M. Ryder, MD, MS
Steven R. Cummings, MD
Lisa Palermo, MS
Suzanne Satterfield, MD, DrPH
Douglas C. Bauer, MD
Adrianne C. Feldstein, MD, MS
John T. Schousboe, MD, MS
Ann V. Schwartz, PhD
Kristine Ensrud, MD, MPH
for the Fracture Intervention Trial Research Group
Publikationsdatum
01.08.2008
Verlag
Springer-Verlag
Erschienen in
Journal of General Internal Medicine / Ausgabe 8/2008
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-008-0622-0

Weitere Artikel der Ausgabe 8/2008

Journal of General Internal Medicine 8/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.